A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs PTC 596 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results (n=31), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Dec 2016 Results (n=18) assessing safety presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 02 Nov 2016 According to a PTC Therapeutics media release, phase 1 safety data was recently presented at the European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top